Viking Therapeutics, Inc. (VKTX) NASDAQ
29.29
-1.98(-6.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Viking Therapeutics, Inc.
Address
9920 Pacific Heights Boulevard
San Diego, CA 92121
United States of America (the)
Phone
858 704 4660
Sector
Healthcare
Industry
Biotechnology
Employees
45
First IPO Date
April 28, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Brian Lian | President, Chief Executive Officer & Director | 1.05M | 1966 |
| Michael Morneau | Vice President of Finance & Administration | 375,333 | 1965 |
| Gregory S. Zante | Chief Financial Officer | 738,000 | 1971 |
| Marianne Mancini | Chief Operating Officer | 765,000 | 1965 |
| Neil Aubuchon | Chief Commercial Officer | 0 | 1971 |
| Geoffrey E. Barker | Chief Development Officer | 0 | N/A |
| Nils U. Olsson | Senior Vice President of Technical Operations | 0 | N/A |
| Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales | 0 | N/A |
| Katherine Mercier | Vice President of Quality and Compliance | 0 | N/A |
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
